In addition, a meta-analysis has shown that the EGFR mutation status may be a predictive biomarker for OS in patients with advanced NSCLC treated with an ICI (i.e., nivolumab, pembrolizumab, or atezolizumab). Here, EGFR is linked to non-small cell lung carcinoma.